Should Cerebral prioritize expanding its medication management services or investing in more diverse talk therapy options for its users?

Introduction

The trade-off question at hand is whether Cerebral should prioritize expanding its medication management services or invest in more diverse talk therapy options for its users. This scenario involves balancing two critical aspects of mental health care delivery in a digital platform. I'll analyze this trade-off by examining the product context, potential impacts, key metrics, and experimental approaches to inform a strategic recommendation.

Step 1

Clarifying Questions (3 minutes)

• Context: I'm thinking Cerebral's current user base might be skewed towards medication management. Could you share the current split between users primarily using medication services versus talk therapy?

Why it matters: Helps understand current demand and potential growth areas Expected answer: 70% medication, 30% talk therapy Impact on approach: A more balanced split might suggest equal investment, while a skew would indicate potential for growth in the underserved area

• Business Context: Based on the competitive landscape, I'm assuming expanding medication management could lead to faster revenue growth. How does our revenue model differ between medication management and talk therapy services?

Why it matters: Informs the financial implications of each option Expected answer: Higher margins on medication management, but longer customer lifetime value with talk therapy Impact on approach: Would influence the balance between short-term gains and long-term sustainability

• User Impact: Considering user needs, I'm hypothesizing that diversifying talk therapy options might improve overall treatment efficacy. Do we have data on treatment outcomes or user satisfaction across both services?

Why it matters: Ensures the decision aligns with improving user outcomes Expected answer: Similar satisfaction rates, but higher retention in users who combine both services Impact on approach: Would emphasize the importance of an integrated approach rather than siloed expansion

• Technical Feasibility: Given the regulatory landscape, I'm assuming expanding medication management services might be more complex. What are the main technical or regulatory challenges for each option?

Why it matters: Identifies potential roadblocks or timeline impacts Expected answer: Stricter regulations for medication management, but more complex matching algorithms for diverse therapy options Impact on approach: Would influence the timeline and resource allocation for each option

• Resource Allocation: Considering our current team structure, I'm thinking we might need to hire differently for each option. What's our current capacity and expertise distribution between medication management and talk therapy?

Why it matters: Determines the feasibility of rapid expansion in either direction Expected answer: Stronger existing team for medication management, but growing expertise in therapy Impact on approach: Would impact the speed of implementation and potential need for external partnerships